AstraZeneca PLC on Thursday said a strong performance in 2025 so far, with third quarter sales ahead of forecast, leaves it well-placed to sustain growth through 2026.
The Cambridge-based pharmaceuticals firm said pretax profit leapt 77% to $3.24 billion in the third quarter from $1.83 billion the year prior, or by 70% at constant currency.
Earnings per share increased 77% to $1.64 from $0.92, with core EPS of $2.38, up 14% from $2.08 a year ago, or 12% at constant currency.
Revenue increased 12% to $15.19 billion from $13.57 billion, or by 10% at constant currency, beating Visible Alpha consensus of $14.80 billion.
This takes revenue for the first nine months of 2025 to $43.24 billion, up 10%, or 11% at constant currency, driven by growth in all therapy areas, including 16% growth in Oncology and 13% growth in Respiratory & Immunology.
Chief Executive Pascal Soriot said: ‘The strong underlying momentum across our business through the first nine months of the year sets us up well to sustain growth through 2026 and has us on track to deliver our 2030 ambition.’
The company has a target of $80 billion in revenue by 2030.
Soriot noted an ‘unprecedented’ 16 positive Phase III trials this year, and said AstraZeneca is also delivering on its strategy to strengthen operations in the US to power growth.
‘This includes a historic agreement with the US government to lower the cost of medicines for American patients, and broadening our US manufacturing footprint having broken ground at our new $4.5 billion Virginia manufacturing facility in October,’ he noted.
In the third quarter, Oncology revenue rose 18% to $6.64 billion, Cardiovascular, Renal & Metabolism sales were flat at $3.22 billion, R&I grew 14% to $2.26 billion, BioPharmaceuticals firmed 4% to $5.90 billion and Rare Diseases climbed by 11% to $2.42 billion - all at constant currency.
Growth was seen across all geographies, with US revenue up 9% at constant currency at $6.55 billion. Emerging Markets excluding China was the star performer, up 25%, while sales in Europe grew 10% also at constant currency. Sales in China rose 5%.
AstraZeneca reiterated guidance for 2025 and expects revenue to increase by a high single-digit percentage and core EPS to increase by a low double-digit percentage.
In 2024, AstraZeneca reported revenue of $54.07 billion and core EPS of $8.21.
Shares in AztraZeneca were up 0.1% at 12,462.00 pence each in London on Thursday morning.
Copyright 2025 Alliance News Ltd. All Rights Reserved.
